Core Insights - The company reported a slight increase in revenue and a significant rise in net profit for the first half of 2025, attributed to both external acquisitions and internal growth driven by AI technology [1][2]. Financial Performance - The company achieved a revenue of 843 million yuan, a year-on-year increase of 2.4% [1]. - The net profit attributable to shareholders was 61.83 million yuan, reflecting a year-on-year growth of 12.8% [1]. Business Segments - The medical services segment generated 653 million yuan in revenue, with the oncology business being a key growth driver, contributing 215 million yuan, a 25.14% increase year-on-year [2]. - The company completed the acquisition of a 51% stake in Changsha Kexin Tumor Hospital for 357 million yuan, enhancing its presence in the central China region [2]. Operational Efficiency - The overall expense ratio decreased by 2 percentage points, while the average service volume per employee increased by 10% [3]. - The company reported an average revenue per employee of 710,000 yuan, up 8.9%, and an average profit per employee of 52,600 yuan, up 20.2% [3]. Market Expansion - The overseas market revenue grew by 35% year-on-year, while the domestic market share also showed steady improvement [3]. - The company achieved significant milestones in product registration and certification, including the EU MDR certification for its third-generation digital mammography machine [3]. Strategic Focus - The company aims to diversify its product offerings across tumor prevention, diagnosis, treatment, and health management to reduce reliance on overseas markets [5].